These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36707253)

  • 21. CRISPR-Cas9 screens identify regulators of antibody-drug conjugate toxicity.
    Tsui CK; Barfield RM; Fischer CR; Morgens DW; Li A; Smith BAH; Gray MA; Bertozzi CR; Rabuka D; Bassik MC
    Nat Chem Biol; 2019 Oct; 15(10):949-958. PubMed ID: 31451760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantifying payloads of antibody‒drug conjugates using a postcolumn infused-internal standard strategy with LC‒MS.
    Cheng CN; Liao HW; Lin CH; Chang WC; Chen IC; Lu YS; Kuo CH
    Anal Chim Acta; 2024 May; 1303():342537. PubMed ID: 38609272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism.
    Shen BQ; Bumbaca D; Saad O; Yue Q; Pastuskovas CV; Khojasteh SC; Tibbitts J; Kaur S; Wang B; Chu YW; LoRusso PM; Girish S
    Curr Drug Metab; 2012 Sep; 13(7):901-10. PubMed ID: 22475269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LC-HRMS quantitation of intact antibody drug conjugate trastuzumab emtansine from rat plasma.
    Jin W; Burton L; Moore I
    Bioanalysis; 2018 Jun; 10(11):851-862. PubMed ID: 29863890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Global Xenobiotic Profiling of Rat Plasma Using Untargeted Metabolomics and Background Subtraction-Based Approaches: Method Evaluation and Comparison.
    Jiang X; Chen S; Zhu M; Wu C
    Curr Drug Metab; 2023; 24(3):200-210. PubMed ID: 37157207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design.
    Maass KF; Kulkarni C; Betts AM; Wittrup KD
    AAPS J; 2016 May; 18(3):635-46. PubMed ID: 26912181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Practical approaches for overcoming challenges in heightened characterization of antibody-drug conjugates with new methodologies and ultrahigh-resolution mass spectrometry.
    Friese OV; Smith JN; Brown PW; Rouse JC
    MAbs; 2018 Apr; 10(3):335-345. PubMed ID: 29393747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
    Lambert JM; Morris CQ
    Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues.
    Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA
    Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical Evaluation of
    Hartimath SV; Alizadeh E; Solomon VR; Chekol R; Bernhard W; Hill W; Parada AC; Barreto K; Geyer CR; Fonge H
    J Nucl Med; 2019 Aug; 60(8):1103-1110. PubMed ID: 30655327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic LC/MS/MS Investigations for the IND-Enabling Extended Characterization of Antibody-Drug Conjugate Modifications.
    Linz T; Yeo D; Hong Q; Zmolek W; McFarland J; Barfield RM; Haskins WE; Rabuka D
    Antibodies (Basel); 2018 Nov; 7(4):. PubMed ID: 31544890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Universal Affinity Capture Liquid Chromatography-Mass Spectrometry Assay for Evaluation of Biotransformation of Site-Specific Antibody Drug Conjugates in Preclinical Studies.
    Kotapati S; Passmore D; Yamazoe S; Sanku RKK; Cong Q; Poudel YB; Chowdari NS; Gangwar S; Rao C; Rangan VS; Cardarelli PM; Deshpande S; Strop P; Dollinger G; Rajpal A
    Anal Chem; 2020 Jan; 92(2):2065-2073. PubMed ID: 31860282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of Antibody-Drug Conjugate Pharmacokinetics and in Vivo Biotransformation Using Quantitative Intact LC-HRMS and Surrogate Analyte LC-MRM.
    Huang Y; Mou S; Wang Y; Mu R; Liang M; Rosenbaum AI
    Anal Chem; 2021 Apr; 93(15):6135-6144. PubMed ID: 33835773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological Evaluation of Maytansinoid-Based Site-Specific Antibody-Drug Conjugate Produced by Fully Chemical Conjugation Approach: AJICAP®.
    Seki T; Yamada K; Ooba Y; Fujii T; Narita T; Nakayama A; Kitahara Y; Mendelsohn BA; Matsuda Y; Okuzumi T
    Front Biosci (Landmark Ed); 2022 Aug; 27(8):234. PubMed ID: 36042175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells.
    Singh R; Setiady YY; Ponte J; Kovtun YV; Lai KC; Hong EE; Fishkin N; Dong L; Jones GE; Coccia JA; Lanieri L; Veale K; Costoplus JA; Skaletskaya A; Gabriel R; Salomon P; Wu R; Qiu Q; Erickson HK; Lambert JM; Chari RV; Widdison WC
    Mol Cancer Ther; 2016 Jun; 15(6):1311-20. PubMed ID: 27197308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability.
    Hamblett KJ; Le T; Rock BM; Rock DA; Siu S; Huard JN; Conner KP; Milburn RR; O'Neill JW; Tometsko ME; Fanslow WC
    Mol Pharm; 2016 Jul; 13(7):2387-96. PubMed ID: 27248573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two-Dimensional Liquid Chromatography Coupled to High-Resolution Mass Spectrometry for the Analysis of ADCs.
    Chapel S; Rouvière F; Sarrut M; Heinisch S
    Methods Mol Biol; 2020; 2078():163-185. PubMed ID: 31643056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of Antibody-Drug Conjugate Released Payload Species Using Directed in Vitro Assays and Mass Spectrometric Interrogation.
    Bessire AJ; Ballard TE; Charati M; Cohen J; Green M; Lam MH; Loganzo F; Nolting B; Pierce B; Puthenveetil S; Roberts L; Schildknegt K; Subramanyam C
    Bioconjug Chem; 2016 Jul; 27(7):1645-54. PubMed ID: 27206324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1.
    Khot A; Tibbitts J; Rock D; Shah DK
    AAPS J; 2017 Nov; 19(6):1715-1734. PubMed ID: 28808917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.